fractional flow reserve for lesion assessment in saphenous vein grafts.

Although the primary analysis in our study focused on ticagrelor dual antiplatelet therapy vs aspirin, ticagrelor monotherapy was compared with aspirin in a supplementary analysis and with both aspirin and ticagrelor dual antiplatelet therapy in a post hoc network meta-analysis. In all these analyses, ticagrelor monotherapy was not associated with a significantly reduced risk of saphenous vein graft failure compared with aspirin.

Sigrid Sandner, MD
Björn Redfors, MD, PhD
Mario Gaudino, MD, PhD

Author Affiliations: Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria (Sandner); Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden (Redfors); Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York (Gaudino).

Corresponding Author: Mario Gaudino, MD, PhD, Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York Presbyterian Hospital, 525 E 68th St, New York, NY 10065 (mfg9004@med.cornell.edu).

Conflict of Interest Disclosures: Dr Sandner reported receiving institutional research grants from Vascular Grafts Solutions. No other disclosures were reported.


CORRECTION

Error in Table: The JAMA Diagnostic Test Interpretation titled “Serum Cystatin C for Estimation of GFR,” published in the August 8, 2022, issue of JAMA, included an error in the SI conversion in Table 1. The Table has been corrected online and now indicates the correct SI conversion for creatinine to μmol/L.


Incorrect Data: The Original Investigation titled “Effect of a Postoperative Multimodal Opioid-Sparing Protocol vs Standard Opioid Prescribing on Postoperative Opioid Consumption After Knee or Shoulder Arthroscopy: A Randomized Trial” published in the October 4, 2022, issue of JAMA included incorrect data. In the results section, the number of patients in the opioid-sparing groups who requested more opioids was incorrect and the data points were incorrectly placed in Figure 2. This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgment and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editors: Jody W. Zylke, MD, Deputy Editor; Kristin Walter, MD, Senior Editor.